Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.
OBJECTIVE
There is increasing evidence that serum lipoprotein cholesterol biomarkers are associated with disease progression in clinically isolated syndromes (CIS). Apolipoproteins (Apo) are recognition ligands that mediate the physiological interactions of cholesterol-containing lipoproteins. The objective of this study was to investigate whether serum Apo levels are associated with CIS disease progression.


METHODS
ApoB, ApoAI, ApoAII, ApoE and lipoprotein (a) (Lpa) levels were measured in serum samples obtained prior to the start of treatment from 181 CIS patients (123 women, 58 men, 68% women; mean age: 28.1±SD 8.1 years). All patients were treated with intramuscular interferon-β as part of the prospective study. Clinical and MRI assessments were obtained at baseline, 6, 12 and 24 months after start of interferon-β treatment.


RESULTS
Greater ApoB levels were associated with increased number of new T2 lesions (p<0.001) and increased number of new or enlarging T2 lesions (p<0.001) over 2 years. Each 10 mg/dL of greater baseline ApoB is associated with a 16% increase in the number of new T2 lesions over 2 years. ApoAI, ApoAII, ApoE and Lpa were not associated with T2 lesions. Greater ApoE levels were associated with greater deep grey matter atrophy (partial correlation rp=-0.28, p<0.001). Each 1 mg/dL increment in ApoE levels was associated with a 1% increase in deep grey matter atrophy over 2 years.


CONCLUSIONS
Serum ApoB levels are associated with new lesion accumulation whereas ApoE levels are associated with deep grey matter atrophy in high risk CIS patients treated with interferon β-1a.
Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, New York, USA.
Richard W
RW
Browne
Department of Neurology, State University of New York, Buffalo, New York, USA.
Bianca
B
Weinstock-Guttman
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Dana
D
Horakova
Department of Neurology, State University of New York, Buffalo, New York, USA Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
Robert
R
Zivadinov
Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, New York, USA.
Mary Lou
ML
Bodziak
Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
Miriam
M
Tamaño-Blanco
Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
Darlene
D
Badgett
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Michaela
M
Tyblova
Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Manuela
M
Vaneckova
Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Zdenek
Z
Seidl
Department of Radiology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Jan
J
Krasensky
Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
Niels
N
Bergsland
Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
Deepa P
DP
Ramasamy
Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, New York, USA.
Jesper
J
Hagemeier
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
Eva
E
Havrdova
Department of Neurology, State University of New York, Buffalo, New York, USA Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York, USA.
Murali
M
Ramanathan
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001053:Apolipoproteins / Q000378:metabolism*; D001057:Apolipoproteins E / Q000097:blood; D001284:Atrophy; D001921:Brain / Q000473:pathology*; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000378:metabolism* / Q000473:pathology*; D011446:Prospective Studies; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D001053:Apolipoproteins; D001057:Apolipoproteins E; D008055:Lipids; D008775:Methylprednisolone
Apolipoproteins; Cholesterol; Interferon; MRI; Multiple Sclerosis